Beacon Investment Advisory Services’s AstraZeneca AZN Stock Holding History

Beacon Investment Advisory Services’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$767K	Hold	4,043	–	–	0.03%	151
2026 Q1	$797K	Sell	4,043 -1	-0%	-$193	0.03%	147
2025 Q4	$743K	Hold	4,044	–	–	0.03%	147
2025 Q3	$620K	Hold	4,044	–	–	0.03%	162
2025 Q2	$565K	Buy	4,044 +319	+9%	+$44.7K	0.02%	163
2025 Q1	$548K	Buy	3,725 +219	+6%	+$31.7K	0.03%	160
2024 Q4	$459K	Buy	3,506 +6	+0.2%	+$840	0.02%	174
2024 Q3	$545K	Sell	3,500 -10	-0.3%	-$1.61K	0.02%	169
2024 Q2	$547K	Buy	3,510 +10	+0.3%	+$1.5K	0.02%	168
2024 Q1	$474K	Hold	3,500	–	–	0.02%	181
2023 Q4	$471K	Hold	3,500	–	–	0.02%	185
2023 Q3	$474K	Hold	3,500	–	–	0.02%	194
2023 Q2	$501K	Hold	3,500	–	–	0.02%	196
2023 Q1	$486K	Hold	3,500	–	–	0.02%	189
2022 Q4	$475K	Hold	3,500	–	–	0.02%	190
2022 Q3	$384K	Hold	3,500	–	–	0.02%	204
2022 Q2	$462K	Sell	3,500 -79	-2%	-$10.4K	0.02%	200
2022 Q1	$474K	Sell	3,579 -55	-2%	-$6.6K	0.02%	213
2021 Q4	$423K	Buy	3,634 +55	+2%	+$6.47K	0.02%	227
2021 Q3	$430K	Sell	3,579 -40	-1%	-$4.66K	0.02%	220
2021 Q2	$434K	Sell	3,619 -128	-3%	-$14K	0.02%	221
2021 Q1	$373K	Sell	3,747 -488	-12%	-$49.1K	0.02%	228
2020 Q4	$423K	Sell	4,235 -1,417	-25%	-$150K	0.02%	199
2020 Q3	$619K	Buy	5,652 +277	+5%	+$30.8K	0.03%	163
2020 Q2	$569K	Buy	5,375 +1,702	+46%	+$176K	0.03%	161
2020 Q1	$328K	Hold	3,673	–	–	0.02%	186
2019 Q4	$366K	Buy	3,673 +173	+5%	+$16.3K	0.02%	204
2019 Q3	$312K	Hold	3,500	–	–	0.03%	193
2019 Q2	$289K	Sell	3,500 -5,000	-59%	-$392K	0.03%	190
2019 Q1	$687K	Sell	8,500 -245	-3%	-$19.3K	0.07%	125
2018 Q4	$664K	Sell	8,745 -21	-0.2%	-$1.64K	0.07%	137
2018 Q3	$694K	Sell	8,766 -3,474	-28%	-$263K	0.07%	131
2018 Q2	$859K	Sell	12,240 -134	-1%	-$9.64K	0.09%	123
2018 Q1	$865K	Buy	12,374 +1,700	+16%	+$118K	0.09%	124
2017 Q4	$741K	Sell	10,674 -3,457	-24%	-$233K	0.08%	128
2017 Q3	$957K	Buy	14,131 +10,159	+256%	+$642K	0.08%	133
2017 Q2	$271K	Buy	3,972 +186	+5%	+$12.1K	0.05%	93
2017 Q1	$236K	Buy	3,786 +27	+0.7%	+$1.57K	0.05%	77
2016 Q4	$205K	Buy	3,759 +28	+0.8%	+$1.59K	0.04%	73
2016 Q3	$245K	Buy	3,731 +163	+5%	+$10.7K	0.05%	63
2016 Q2	$215K	Hold	3,568	–	–	0.05%	67
2016 Q1	$201K	Buy	3,568 +112	+3%	+$6.73K	0.04%	62
2015 Q4	$235K	Hold	3,456	–	–	0.04%	58
2015 Q3	$220K	Buy	+3,456	New	+$227K	0.04%	59

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Beacon Investment Advisory Services's AZN Position: Q2 2026 in Review

Beacon Investment Advisory Services held its AstraZeneca (AZN) position steady in Q2 2026 at 4,043 shares worth $767K. The position accounts for 0.03% of the portfolio, ranked #151.

Beacon Investment Advisory Services first reported a position in AZN in Q3 2015 and has held it in 44 quarters since. The position peaked at $957K in Q3 2017. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Beacon Investment Advisory Services held 4,043 shares of AstraZeneca worth $767K as of Q2 2026.
Beacon Investment Advisory Services left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.03% of Beacon Investment Advisory Services's portfolio in Q2 2026, its #151 holding.
Beacon Investment Advisory Services first reported a position in AstraZeneca in Q3 2015 and has held it in 44 quarters since.
Beacon Investment Advisory Services's AstraZeneca position peaked at $957K in Q3 2017.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Beacon Investment Advisory Services's 13F filing for Q2 2026, filed 8 Jul 2026.